Skip to main content

Table 2 Baseline characteristics of synchronous metastatic colorectal cancer patients by EGFR expression and KRAS mutation status

From: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

Characteristic EGFR positive (%) EGFR negative (%) Pvalue KRASWTa(%) KRASMutb(%) Pvalue
N = 73 (88.0%) N = 17 (12.0%) N = 63 (58.9%) N = 44 (4119%)
Age (years, mean ± SD) 61.14 ± 11.81 65.80 ± 8.05 0.231 61.83 ± 10.49 61.86 ± 13.93 0.987
Gender    0.787    0.119
Male 47 (64.4) 6 (60.0)   35 (55.6) 31 (70.5)  
Female 26 (35.6) 4 (40.0)   28 (44.4) 13 (29.5)  
Tumor size    0.047    0.134
≥5 cm 39 (53.4) 2 (20.0)   28 (44.4) 26 (59.1)  
<5 cm 34 (46.6) 8 (80.0)   35 (55.6) 18 (40.9)  
Tumor location    0.055    0.098
Colon 62 (84.9) 6 (60.0)   46 (73.0) 38 (86.4)  
Rectum 11 (15.1) 4 (40.0)   17 (27.0) 6 (13.6)  
Histology    0.862    0.873
Well 2 (2.7) 0 (00.0)   2 (3.2) 1 (2.3) 0.873
Moderately 58 (79.5) 8 (80.0)   49 (77.8) 36 (81.8)  
Poorly 13 (17.8) 2 (20.0)   12 (19.0) 7 (15.9)  
Histology    0.866    0.676
Well + Moderately 60 (82.2) 8 (80.0)   51 (81.0) 37 (84.1)  
Poorly 13 (17.8) 2 (20.0)   12 (19.0) 7 (15.9)  
Tumor depth    0.792    0.734
T1 1 (1.4) 0 (0.0)   1 (1.6) 0 (0.0)  
T2 3 (4.1) 1 (10.0)   3 (4.8) 3 (6.8)  
T3 48 (65.7) 7 (70.0)   45 (71.4) 29 (65.9)  
T4 21 (28.8) 2 (20.0)   14 (22.2) 12 (27.3)  
Lymph nodes metastases    0.407    0.824
N0 17 (23.2) 4 (40.0)   14 (22.2) 10 (22.7)  
N1 28 (38.4) 2 (20.0)   25 (39.7) 15 (34.1)  
N2 28 (38.4) 4 (40.0)   24 (38.1) 19 (43.2)  
Retrived LN c 17.09 ± 8.04 14.40 ± 5.85 0.313 16.31 ± 8.36 16.25 ± 8.17 0.971
Vascular invasion    0.756    0.863
Yes 33 (45.2) 4 (40.0)   29 (46.0) 21 (47.7)  
No 40 (54.8) 6 (60.0)   34 (54.0) 23 (52.3)  
Perineurial invasion    0.968    0.539
Yes 36 (49.3) 5 (50.0)   32 (50.8) 25 (56.8) 0.539
No 37 (50.7) 5 (50.0)   31 (49.2) 19 (43.2)  
Pre-op serum CEA b level    0.496    0.827
≥5 ng/ml 58 (79.5) 7 (70.0)   49 (77.8) 35 (79.5)  
<5 ng/ml 15 (20.5) 3 (30.0)   14 (22.2) 9 (20.5)  
Post-op serum CEA b level    0.568    0.799
≥5 ng/ml 21 (28.8) 4 (40.0)   43 (68.3) 29 (65.9)  
<5 ng/ml 46 (71.2) 6 (60.0)   20 (31.7) 15 (34.1)  
Overall survival (months) 22.08 ± 12.38 24.70 ± 9.91 0.523 23.04 ± 12.62 18.74 ± 11.39 0.074
Progression-free survival (months) 9.65 ± 7.44 11.66 ± 6.16 0.417 10.22 ± 7.14 7.95 ± 6.75 0.101
  1. aWT: wild type; bMut: mutation; cLN: lymph node.